Merck's Keytruda Reaches Blockbuster Status, But Still Lags In Lung Cancer
Executive Summary
Merck’s PD-1 inhibitor Keytruda brought in $1.4bn in 2016 and appears poised to take advantage of first-mover status among immuno-oncology agents in first-line NSCLC.
You may also be interested in...
1Q Pharma Results Preview: Merck, Pfizer, Gilead, Novo Nordisk, Shire, Allergan, Teva
Part two of Scrip's preview of first quarter earnings: Recent launches, pricing strategies and biosimilar competition will be key themes as top-tier pharmaceutical companies continue to report first quarter performance.
Access To HCV Therapies Decreasing Despite Pricing Reductions
Data presented by Trio Health covering about 15,000 US hepatitis C patients from 2014 to 2016 show that failure to start treatment increased from 8% to 29%. Denials of coverage by private insurers, Medicare and Medicaid are the main reason driving this trend, the data analysis firm contends.
Stockwatch: Flat Is The New Black For Lilly And Sanofi
A lackluster fourth-quarter earnings season at least didn't get any worse with the reports of Merck, Lilly, Sanofi and GSK. Flat earnings guidance might be considered to be an improvement on guidance cuts, but financial guidance that depends on currency effects and the absence of generic competition may ultimately be unreliable.